Triparna Sen: SCLC augmenting immunotherapy and chemotherapy response
Triparna Sen, Associate Professor at Icahn School of Medicine at Mount Sinai, shared a post on X:
“Honored to have our work on small-cell lung cancer SCLC featured in Mount Sinai Science and Medicine magazine.
Our research has identified targets and pathways in SCLC that can augment immunotherapy and chemotherapy response.
These findings bring hope for new treatments for small-cell lung cancer, one of the most aggressive cancers.
Grateful to my amazing team, collaborators, and Icahn Mount Sinai for their support, and to the patients and caregivers who inspire us every day.
The magazine also highlights the groundbreaking work of my esteemed colleagues, our institution’s commitment to patient care, and its mission to drive innovation in science and medicine.”
Dr. Triparna Sen is an Associate Professor, in the Department of Oncological Sciences, and the Director of the Lung Cancer PDX Platform at the Icahn School of Medicine at Mount Sinai, New York. She leads a multi-disciplinary team of investigators in laboratory-based, patient-focused investigations focused on cancer biology and precision medicine.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023